The historical rank and industry rank for Medigen Vaccine Biologics's Net Margin % or its related term are showing as below:
ROCO:6547'
s Net Margin % Range Over the Past 10 Years
Min: -55153.39 Med: -297.68 Max: 42.98
Current: -45.94
ROCO:6547's Net Margin % is ranked better than 56.3% of 945
companies
in the Biotechnology industry
Industry Median: -89.33
vs ROCO:6547: -45.94
Medigen Vaccine Biologics (ROCO:6547) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Medigen Vaccine Biologics Net Margin % Related Terms
Medigen Vaccine Biologics Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6547 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Medigen Vaccine Biologics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Vaccine Biologics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Medigen Vaccine Biologics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Vaccine Biologics (ROCO:6547) has a Net Margin % of -93.99% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Medigen Vaccine Biologics and its competitors. According to the industry distribution chart, Medigen Vaccine Biologics ranks #413 out of 945 companies in the Biotechnology industry, placing it in the top 43.7%.
Is Medigen Vaccine Biologics' Net Margin % too high?
Medigen Vaccine Biologics' current Net Margin % is -93.99%. Based on the distribution chart, Medigen Vaccine Biologics ranks #413 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medigen Vaccine Biologics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Vaccine Biologics ranks #413 out of 945 companies for Net Margin %. This puts Medigen Vaccine Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Medigen Vaccine Biologics and its competitors. Medigen Vaccine Biologics's current Net Margin % is -93.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Possible Value Trap. The stock's GF Value™ is NT$69.49, compared to a current price of NT$45.45 — trading 34.6% below its estimated fair value. The current Net Margin % is -93.99%. Medigen Vaccine Biologics' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Net Margin % is -93.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued.
The current stock price of NT$45.45 is trading 34.6% below its estimated GF Value™ of NT$69.49.
GuruFocus considers Medigen Vaccine Biologics to be Possible Value Trap.
Key valuation signals for ROCO:6547:
Net Margin %: -93.99%
GF Value™: NT$69.49 vs. price of NT$45.45 (34.6% below fair value)
No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
68GF Score
Get the complete analysis for ROCO:6547
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6547 has been successfully added to your 
